Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (727,952)	$ (1,380,710)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,902	$ 17
Amortization of discounts related to convertible notes payable Investor warrants	82,677
Amortization of discounts related to convertible notes payable Beneficial conversion feature	83,320
Amortization of capitalized financing costs	37,098
Gain on settlements with former management	$ (92,550)	$ (1,038,270)
Stock-based compensation expense included in -
General and administrative expenses		$ 2,280,000
Research and development expenses	$ 72,000
Foreign currency transaction (gain) loss	(4,190)	$ (6,277)
(Increase) decrease in -
Grant receivable	19,417
Prepaid insurance	5,256	$ (124,998)
Increase (decrease) in -
Accounts payable and accrued expenses	327,379	61,613
Accrued compensation and related expenses	(7,500)	(118,084)
Accrued interest payable	24,691	$ 12,950
Unearned grant revenue	(21,951)
Net cash used in operating activities	(200,403)	$ (313,759)
Cash flows from investing activities:
Purchases of equipment	(2,497)	(1,925)
Net cash used in investing activities	$ (2,497)	(1,925)
Cash flows from financing activities:
Proceeds from sale of Series G 1.5% Convertible Preferred Stock		$ 753,220
Proceeds from convertible note and warrant financing	$ 210,000
Proceeds from issuance of notes payable to Chairman		$ 75,000
Repayment of notes payable to Chairman		$ (150,000)
Cash payments made for deferred costs incurred in connection with convertible note and warrant financing	$ (15,700)
Cash payments made for costs incurred in connection with sale of Series G 1.5% Convertible Preferred Stock		$ (64,956)
Net cash provided by financing activities	$ 194,300	613,264
Cash and cash equivalents:
Net increase (decrease)	(8,600)	297,580
Balance at beginning of period	162,752	14,352
Balance at end of period	154,152	$ 311,932
Cash paid for -
Interest	$ 750
Income taxes
Non-cash financing activities:
Amortization of deemed dividend on Series G 1.5% Convertible Preferred Stock		$ 1,209,970
Dividend on Series G 1.5% Convertible Preferred Stock	$ 3,198	$ 408
Short-term note payable issued in connection with the procurement of director and officer insurance	36,125
Stated value of Series G 1.5% Convertible Preferred Stock converted into common stock	25,324
Fair value of common stock options issued in connection with settlements with former management	25,450	$ 179,910
Fair value of common stock warrants issued to investors in connection with the convertible note and warrant financing	112,557
Fair value of common stock warrants issued to finders in connection with the convertible note and warrant financing	12,726
Fair value of beneficial conversion feature of convertible notes payable issued to investors in connection with the convertible note and warrant financing	$ 97,443
Fair value of common stock warrants issued to placement agents and selected dealers in connection with the sale of Series G 1.5% Convertible Preferred Stock		$ 443,848
Deferred financing costs transferred to additional paid-in capital in connection with sale of Series G 1.5% Convertible Preferred Stock		$ 35,120